eflornithine has been researched along with Li-Fraumeni Syndrome in 1 studies
Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.
eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.
Li-Fraumeni Syndrome: Rare autosomal dominant syndrome characterized by mesenchymal and epithelial neoplasms at multiple sites. MUTATION of the p53 tumor suppressor gene, a component of the DNA DAMAGE response pathway, apparently predisposes family members who inherit it to develop certain cancers. The spectrum of cancers in the syndrome was shown to include, in addition to BREAST CANCER and soft tissue sarcomas (SARCOMA); BRAIN TUMORS; OSTEOSARCOMA; LEUKEMIA; and ADRENOCORTICAL CARCINOMA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Herbert, BS | 1 |
| Wright, AC | 1 |
| Passons, CM | 1 |
| Wright, WE | 1 |
| Ali, IU | 1 |
| Kopelovich, L | 1 |
| Shay, JW | 1 |
1 other study available for eflornithine and Li-Fraumeni Syndrome
| Article | Year |
|---|---|
Effects of chemopreventive and antitelomerase agents on the spontaneous immortalization of breast epithelial cells.
Topics: Antineoplastic Agents; Breast; Breast Neoplasms; Cell Division; Cell Transformation, Neoplastic; Cel | 2001 |